Omid Hamid

83.4k total citations · 18 hit papers
414 papers, 26.3k citations indexed

About

Omid Hamid is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Omid Hamid has authored 414 papers receiving a total of 26.3k indexed citations (citations by other indexed papers that have themselves been cited), including 355 papers in Oncology, 156 papers in Molecular Biology and 129 papers in Immunology. Recurrent topics in Omid Hamid's work include Cancer Immunotherapy and Biomarkers (216 papers), CAR-T cell therapy research (176 papers) and Melanoma and MAPK Pathways (114 papers). Omid Hamid is often cited by papers focused on Cancer Immunotherapy and Biomarkers (216 papers), CAR-T cell therapy research (176 papers) and Melanoma and MAPK Pathways (114 papers). Omid Hamid collaborates with scholars based in United States, France and Australia. Omid Hamid's co-authors include F. Stephen Hodi, Jeffrey S. Weber, Jedd D. Wolchok, Steven O’Day, Caroline Robert, Célèste Lebbé, David M. Berman, Adil Daud, Michele Maio and Antoni Ribas and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Omid Hamid

396 papers receiving 25.9k citations

Hit Papers

Guidelines for the Evaluation of Immune Therapy Activity ... 2009 2026 2014 2020 2009 2015 2016 2017 2012 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
    2009 2.3k citations Jedd D. Wolchok, Axel Hoos et al. Clinical Cancer Research profile →
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    2015 1.6k citations Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
  3. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    2016 933 citations Howard L. Kaufman, Omid Hamid et al. profile →
  4. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Antoni Ribas, Georgina V. Long et al. profile →
  5. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
    2012 826 citations Omid Hamid, Donald P. Lawrence et al. profile →
  6. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
  7. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →
  8. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    2019 703 citations Georgina V. Long, Omid Hamid et al. profile →
  9. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    2016 661 citations Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology profile →
  10. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    2019 638 citations Omid Hamid, Caroline Robert et al. profile →
  11. An immune-active tumor microenvironment favors clinical response to ipilimumab
    2011 593 citations Omid Hamid, Henrik Schmidt et al. profile →
  12. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
    2017 471 citations Jason Chesney, Igor Puzanov et al. Journal of Clinical Oncology profile →
  13. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    2013 436 citations Omid Hamid et al. profile →
  14. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
    2016 435 citations Igor Puzanov, Mohammed Milhem et al. Journal of Clinical Oncology profile →
  15. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
    2014 416 citations Omid Hamid et al. profile →
  16. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
    2016 409 citations David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology profile →
  17. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
    2015 382 citations Gerald S. Falchook, Eunice L. Kwak et al. Journal of Clinical Oncology profile →
  18. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
    2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Omid Hamid United States 68 21.3k 9.8k 8.0k 4.9k 1.9k 414 26.3k
Christina B. Walter Germany 6 18.1k 0.9× 8.9k 0.9× 6.7k 0.8× 6.3k 1.3× 4.5k 2.4× 13 25.0k
Florin‐Andrei Taran Germany 23 18.6k 0.9× 8.9k 0.9× 6.8k 0.9× 6.6k 1.3× 4.9k 2.6× 77 26.3k
Achim A. Jungbluth United States 76 10.1k 0.5× 9.9k 1.0× 7.8k 1.0× 3.6k 0.7× 1.7k 0.9× 285 20.9k
Mario Sznol United States 67 13.8k 0.7× 7.8k 0.8× 5.6k 0.7× 4.3k 0.9× 1.6k 0.8× 270 19.8k
Padmanee Sharma United States 63 20.0k 0.9× 13.9k 1.4× 6.5k 0.8× 5.8k 1.2× 2.9k 1.5× 257 28.5k
Andreas D. Hartkopf Germany 24 19.3k 0.9× 9.0k 0.9× 7.1k 0.9× 6.8k 1.4× 5.5k 3.0× 169 26.9k
Robert H. Vonderheide United States 74 15.2k 0.7× 14.2k 1.4× 6.9k 0.9× 2.4k 0.5× 3.2k 1.7× 224 25.0k
Daniel S. Chen United States 29 13.3k 0.6× 8.5k 0.9× 5.1k 0.6× 4.6k 0.9× 2.6k 1.4× 50 20.1k
Eva‐Maria Grischke Germany 24 20.6k 1.0× 9.0k 0.9× 7.6k 0.9× 8.4k 1.7× 5.5k 3.0× 126 29.4k
James L. Gulley United States 71 11.7k 0.5× 8.3k 0.8× 4.2k 0.5× 5.7k 1.2× 1.8k 1.0× 568 18.4k

Countries citing papers authored by Omid Hamid

Since Specialization
Citations

This map shows the geographic impact of Omid Hamid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omid Hamid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omid Hamid more than expected).

Fields of papers citing papers by Omid Hamid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omid Hamid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omid Hamid. The network helps show where Omid Hamid may publish in the future.

Co-authorship network of co-authors of Omid Hamid

This figure shows the co-authorship network connecting the top 25 collaborators of Omid Hamid. A scholar is included among the top collaborators of Omid Hamid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omid Hamid. Omid Hamid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nijenhuis, Cynthia M., Inge Jedema, Justin T. Moyers, et al.. (2025). Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products. Transplantation and Cellular Therapy. 31(3). S610–S625. 3 indexed citations
2.
Wehrenberg-Klee, Eric, Antoine Desîlets, Marlana Orloff, et al.. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 30(10).
3.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591. 7 indexed citations
4.
Zamarin, Dmitriy, Omid Hamid, Asha Nayak-Kapoor, et al.. (2020). Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 26(17). 4531–4541. 52 indexed citations
5.
Middleton, Mark R., Cheryl McAlpine, Victoria K. Woodcock, et al.. (2020). Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research. 26(22). 5869–5878. 165 indexed citations
6.
Hamid, Omid, Luciana Molinero, Christopher R. Bolen, et al.. (2019). Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research. 25(20). 6061–6072. 58 indexed citations
7.
Ribas, Antoni, Adil Daud, Anna C. Pavlick, et al.. (2019). Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma. Clinical Cancer Research. 26(1). 46–53. 30 indexed citations
8.
Hong, David S., Patricia LoRusso, Omid Hamid, et al.. (2018). Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 25(8). 2403–2413. 42 indexed citations
9.
Sekulić, Aleksandar, Michael R. Migden, Nicole Basset‐Séguin, et al.. (2017). Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 17(1). 332–332. 283 indexed citations
10.
Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations
11.
Massard, Christophe, Michael S. Gordon, Sunil Sharma, et al.. (2016). Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology. 34(26). 3119–3125. 661 indexed citations breakdown →
12.
Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936. 281 indexed citations breakdown →
13.
Puzanov, Igor, Mohammed Milhem, David R. Minor, et al.. (2016). Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology. 34(22). 2619–2626. 435 indexed citations breakdown →
14.
Carvajal, Richard D., Donald P. Lawrence, Jeffrey S. Weber, et al.. (2015). Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research. 21(10). 2289–2296. 97 indexed citations
15.
Falchook, Gerald S., Georgina V. Long, Razelle Kurzrock, et al.. (2014). Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research. 20(17). 4449–4458. 51 indexed citations
16.
Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations
17.
Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations
18.
Hamid, Omid & Gary Goldenberg. (2013). Identifying patients at risk for recurrent or advanced BCC.. PubMed. 12(11). 1246–52; quiz 1253. 10 indexed citations
19.
Wolchok, Jedd D., Axel Hoos, Steven O’Day, et al.. (2009). Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research. 15(23). 7412–7420. 2308 indexed citations breakdown →
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina B. Walter Breakdown of academic impact, for papers by Florin‐Andrei Taran Breakdown of academic impact, for papers by Achim A. Jungbluth Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Padmanee Sharma Breakdown of academic impact, for papers by Andreas D. Hartkopf Breakdown of academic impact, for papers by Robert H. Vonderheide Breakdown of academic impact, for papers by Daniel S. Chen Breakdown of academic impact, for papers by Eva‐Maria Grischke Breakdown of academic impact, for papers by James L. Gulley
Rankless by CCL
2026